BGB-10188 is under clinical development by BeiGene and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase II drugs for Esophageal Cancer have a 25% phase transition success ...
Castle Biosciences’ TissueCypher® test can offer patients with Barrett’s esophagus a clearer picture of their risk of developing esophageal cancer. Esophageal cancer is a killer. It’s the ...
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
Waltham, Massachusetts, firefighters are participating in a new screening initiative to detect esophageal precancer due to the increased occupational cancer risk.